Polyp (medicine)

Optinose Announces $55 Million Registered Direct Offering

Retrieved on: 
木曜日, 5月 9, 2024
Sale, FDA, Prospectus, Sinusitis, ENT, Nose, OPTN, Patient, MPH, Ear, Polyp (medicine), Security (finance)

YARDLEY, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into agreements for the sale of approximately $55 million of its common stock and pre-funded common stock warrants to a group of existing and new institutional investors in a registered direct offering.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $55 million, before deducting estimated offering expenses.
  • The registered direct offering is expected to close on or about May 10, 2024, subject to the satisfaction of customary closing conditions.
  • We expect the post-offering cash and cash equivalents of approximately $100 million to fund operations and debt service obligations through 2025.
  • A preliminary prospectus supplement relating to the offering was filed with the SEC on May 9, 2024 and is available on the SEC’s website at www.sec.gov.

AAFA Co-Hosts Congressional Briefing Highlighting 25th Year of National Asthma Control Program

Retrieved on: 
火曜日, 5月 7, 2024
Mortality, Public, Climate change, United, Allergist, Risk, CDC, Health, Pollen, Congress, NACP, Dingell, AAFA, Public policy, Food, Air pollution, Legislation, World Asthma Day, Anaphylaxis, Alaska Natives, Allergy, Atopic dermatitis, Quality of life, Polyp (medicine), Eosinophilic esophagitis, COVID-19, Calendar, RSV, Pharmaceutical industry

Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma Day (May 7) by co-hosting a Congressional briefing highlighting the program’s impact and calling attention to the need to expand the program to all of the United States.

Key Points: 
  • Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma Day (May 7) by co-hosting a Congressional briefing highlighting the program’s impact and calling attention to the need to expand the program to all of the United States.
  • “The NACP provides resources for asthma education that help empower people with asthma,” said Kenneth Mendez, president and CEO of AAFA.
  • And for every $1 spent, the NACP saves $71 in total economic costs related to asthma.
  • On behalf of the 27 million people in the US with asthma, we’re grateful for the positive impact NACP has made over the past 25 years.

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

Retrieved on: 
水曜日, 5月 1, 2024
AMGN, MPA, Effectiveness, Political moderate, Prednisone, ATS, Chronic obstructive pulmonary disease, Emphysema, Polyp (medicine), Inflammation, Hospital, Exercise, ANCA, Post hoc analysis, Abstract, PDT, Research and development, Biomarker, Initiation, Conference, Development, Literature, Vasculitis, History, GPA, Clinical, Amgen, Bronchitis, COPD, Pharmaceutical industry

THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.

Key Points: 
  • THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego.
  • Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.
  • "Our efforts underscore Amgen's commitment to pioneering new treatments for respiratory diseases with currently limited treatment options."
  • Data from the COURSE trial will be presented within the Clinical Trials Symposium.

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

Retrieved on: 
木曜日, 4月 25, 2024
FDA, Sinusitis, CS, ENT, Nose, Webcast, OPTN, Patient, MPH, Physician, Fluticasone, Ear, Telephone, Polyp (medicine), GAAP, Growth, Pharmaceutical industry

The Company will host an investor call at 10:00 a.m. Eastern Time today to discuss its commercial strategy and financial outlook.

Key Points: 
  • The Company will host an investor call at 10:00 a.m. Eastern Time today to discuss its commercial strategy and financial outlook.
  • In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31, 2024, representing growth of approximately 26% over the first quarter of 2023.
  • “The recent FDA approval of XHANCE as the first and only approved drug treatment for chronic sinusitis (CS) is a landmark achievement,” said Ramy Mahmoud, MD, MPH, CEO of Optinose.
  • In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
水曜日, 5月 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Retrieved on: 
木曜日, 4月 11, 2024
Health, FDA, General Health, Research, Science, Pharmaceutical, Biotechnology, Efficacy, Safety, Gastroenterology, HES, Chronic obstructive pulmonary disease, Sinusitis, Social media, Polyp (medicine), Pharmacokinetics, Rheumatology, Conference call, Asthma, TATE, AstraZeneca, FY, Hypereosinophilic syndrome, Death, ClinicalTrials.gov, Dermatology, Conference, COPD, Webcast, Growth, Disease, Vasculitis, Respiratory Medicine, EGPA, Immunology, Metabolism, Diagnosis, Biomarker, PD, Biopharmaceutical, Ageing, Pharmaceutical industry

TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.

Key Points: 
  • TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.
  • The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.
  • Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study).
  • Severe uncontrolled asthma in children: practical approach on diagnosis and management.

ModMed & Medtronic Collaborate to Drive Efficiencies in Documenting Colonoscopies Using AI

Retrieved on: 
水曜日, 4月 10, 2024
Surgery, General Health, Health, Artificial Intelligence, Medical Devices, Hospitals, Health Technology, Technology, Cancer, Endoscopy, Capital, AI, ENT, Thought, EHR, Artificial intelligence, Polyp (medicine), Medtronic, Documentation, Patient, Physician, Colonoscopy, Multimedia, Nursing

Practice technology leader and EHR pioneer ModMed ® announced today that it will collaborate with Medtronic, the world’s largest medtech company, to enhance the documentation of polyp detection by utilizing the AI capabilities of the GI Genius system sold by Medtronic.

Key Points: 
  • Practice technology leader and EHR pioneer ModMed ® announced today that it will collaborate with Medtronic, the world’s largest medtech company, to enhance the documentation of polyp detection by utilizing the AI capabilities of the GI Genius system sold by Medtronic.
  • View the full release here: https://www.businesswire.com/news/home/20240410782785/en/
    Practice technology leader and EHR pioneer ModMed® announced today that it will collaborate with Medtronic, the world’s largest medtech company, to enhance the documentation of polyp detection by utilizing the AI capabilities of the GI Genius system sold by Medtronic.
  • ModMed supports this goal and believes that additional efficiency can be built into the colonoscopy process.
  • "Our goal is to ensure that physicians have more time to focus on patients by building efficiency into the documentation process.

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

Retrieved on: 
水曜日, 4月 10, 2024
Cade, Endoscopy, Publication, AI, Thought, EHR, Gastroenterology, Artificial intelligence, Workflow, Electronic health record, Polyp (medicine), Medtronic, GI, Documentation, Health information management, Data, Patient, Physician, Health, Standard of care, Medical device

DUBLIN, April 10, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

Key Points: 
  • GI Genius™ was the first commercially available computer-aided detection (CADe) system used AI to identify colorectal polyps.
  • The update also provides user interface enhancements to support the development of third-party applications through the AI Access™ platform , introduced at last year's Genius Summit.
  • Medtronic's announcements at the Genius Summit underscore its dedication to advancing colorectal cancer care with AI innovations and strategic collaborations.
  • Medtronic remains at the forefront of delivering solutions that address the needs of patients and physicians alike.

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Retrieved on: 
金曜日, 3月 15, 2024
Nosebleed, Research, Polyp (medicine), Vanderbilt University, Sciatica, Fluticasone, Education, Drainage, Disease, Incidence, Headache, Inflammation, Patient, Conditional sentence, Chronic obstructive pulmonary disease, Sinusitis, CRS, Standard of care, Quality of life, Migraine, Nasal cavity, Ear, ENT, Service, MPH, Nose, OPTN, FDA, Frustration, Food, Pharmaceutical industry

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Key Points: 
  • Chronic sinusitis (also called “chronic rhinosinusitis” or “CRS”) is one of the most common chronic diseases, affecting approximately 30 million adults in the United States.
  • Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine.
  • Chronic sinusitis is also one of the most common diagnoses in adult outpatient medicine.
  • Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually.

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Retrieved on: 
水曜日, 3月 13, 2024
COL7, FAP, Cancer, Patient, APC, Mouse, ALM, Ribosome, BME, Gastrointestinal disease, OTC, Skin, Polyp (medicine), Therapy, Kidney, Pharmaceutical industry

BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.

Key Points: 
  • BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.
  • Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases.
  • ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.
  • The drug candidate is expected to shortly enter into Phase I development in healthy volunteers.